TY - JOUR
T1 - Sex, clinical symptoms, and angiographic findings in patients with diabetes mellitus and coronary artery disease (from the Bypass Angioplasty Revascularization Investigation [BARI] 2 Diabetes Trial)
AU - Tamis-Holland, Jacqueline E.
AU - Lu, Jiang
AU - Bittner, Vera
AU - Magee, Michelle F.
AU - Lopes, Neuza
AU - Adler, Dale S.
AU - Kip, Kevin E.
AU - Schwartz, Leonard
AU - Groenewoud, Yolanda A.
AU - Jacobs, Alice K.
N1 - Funding Information:
BARI 2D was funded by the National Heart, Lung and Blood Institute and the National Institute of Diabetes and Digestive and Kidney Diseases , Nos. U01 HL061744 , U01 HL061746 , U01 HL061748 , and U01 HL063804 . Significant supplemental funding was provided by GlaxoSmithKline , Collegeville, Pennsylvania, Lantheus Medical Imaging, Inc. (formerly Bristol-Myers Squibb Medical Imaging, Inc.), North Billerica, Massachusetts, Astellas Pharma US, Inc. (formerly Fujisawa Pharmaceutical Co., Ltd.), Deerfield, Illinois, Merck & Co., Inc. , Whitehouse Station, New Jersey, Abbott Laboratories, Inc. , Abbott Park, Illinois, and Pfizer, Inc , New York, New York. Generous support was given by Abbott Laboratories Ltd. , MediSense Products , Mississauga, Canada, Bayer Diagnostics , Tarrytown, New York, Becton, Dickinson and Company , Franklin Lakes, New Jersey, J.R. Carlson Labs , Arlington Hts., Illinois, Centocor, Inc. , Malvern, Pennsylvania, Eli Lilly and Company , Indianapolis, Indiana, LipoScience, Inc. , Raleigh, North Carolina, Merck Sante, Lyon, France, Novartis Pharmaceuticals Corporation , East Hanover, New Jersey, and Novo Nordisk, Inc. , Princeton, New Jersey.
PY - 2011/4/1
Y1 - 2011/4/1
N2 - Previous studies have reported differences in presenting symptoms and angiographic characteristics between women and men undergoing evaluation for suspected coronary artery disease (CAD). We examined the relation between symptoms and extent of CAD in patients with type 2 diabetes mellitus and known CAD enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Of 1,775 patients (533 women, 30%, and 1,242 men, 70%), women were more likely than men to have angina (65% vs 56%, p <0.001) or an atypical angina/anginal equivalent (71% vs 58%, p <0.001). More women reported unstable angina (17% vs 13%, p = 0.047) or were in a higher Canadian Cardiology Society class compared to men (Canadian Cardiology Society classes II to IV 78% vs 68%, p = 0.002). Fewer women than men had no symptoms (14% vs 22%, p <0.001). Women had a lower mean myocardial jeopardy index (42.5 ± 24.3 vs 47.9 ± 24.3, p <0.001), smaller number of total significant lesions (2.3 ± 1.7 vs 2.7 ± 1.8, p <0.001), and fewer jeopardized left ventricular regions (p <0.001 for distribution) or long-term occlusions (29% vs 42%, p <0.001). After adjustment for relevant covariates, the odds of having CAD symptoms were still higher in women than men (odds ratio for angina 1.31, 95% confidence interval 1.02 to 1.69; odds ratio for atypical angina 1.52, 95% confidence interval 1.17 to 1.96). In conclusion, in a high-risk group of patients with known CAD and diabetes mellitus, women were more symptomatic than men but had less obstructive CAD. These data suggest that factors other than epicardial CAD severity influence symptom presentation in women in this population.
AB - Previous studies have reported differences in presenting symptoms and angiographic characteristics between women and men undergoing evaluation for suspected coronary artery disease (CAD). We examined the relation between symptoms and extent of CAD in patients with type 2 diabetes mellitus and known CAD enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Of 1,775 patients (533 women, 30%, and 1,242 men, 70%), women were more likely than men to have angina (65% vs 56%, p <0.001) or an atypical angina/anginal equivalent (71% vs 58%, p <0.001). More women reported unstable angina (17% vs 13%, p = 0.047) or were in a higher Canadian Cardiology Society class compared to men (Canadian Cardiology Society classes II to IV 78% vs 68%, p = 0.002). Fewer women than men had no symptoms (14% vs 22%, p <0.001). Women had a lower mean myocardial jeopardy index (42.5 ± 24.3 vs 47.9 ± 24.3, p <0.001), smaller number of total significant lesions (2.3 ± 1.7 vs 2.7 ± 1.8, p <0.001), and fewer jeopardized left ventricular regions (p <0.001 for distribution) or long-term occlusions (29% vs 42%, p <0.001). After adjustment for relevant covariates, the odds of having CAD symptoms were still higher in women than men (odds ratio for angina 1.31, 95% confidence interval 1.02 to 1.69; odds ratio for atypical angina 1.52, 95% confidence interval 1.17 to 1.96). In conclusion, in a high-risk group of patients with known CAD and diabetes mellitus, women were more symptomatic than men but had less obstructive CAD. These data suggest that factors other than epicardial CAD severity influence symptom presentation in women in this population.
UR - http://www.scopus.com/inward/record.url?scp=79952774958&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2010.11.020
DO - 10.1016/j.amjcard.2010.11.020
M3 - Article
AN - SCOPUS:79952774958
SN - 0002-9149
VL - 107
SP - 980
EP - 985
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 7
ER -